JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.

Detalles Bibliográficos
Autores principales: Degryse, Sandrine, Cools, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545857/
https://www.ncbi.nlm.nih.gov/pubmed/26208852
http://dx.doi.org/10.1186/s13045-015-0192-7
Descripción
Sumario:Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.

Ejemplares similares